H.C. Wainwright lowered the firm’s price target on uniQure (QURE) to $70 from $110 and keeps a Buy rating on the shares. The firm says the FDA’s shift on AMT-130 is a significant but surmountable. It is confident that a viable regulatory path should emerge. The selloff yesterday in uniQure shares overstates the fundamental impact of the news, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QURE:
- William Blair downgrades uniQure on uncertain path forward
- uniQure downgraded to Market Perform from Outperform at William Blair
- uniQure price target lowered to $53 from $76 at Chardan
- uniQure price target lowered to $45 from $65 at RBC Capital
- Morning News Wrap-Up: Monday’s Biggest Stock Market Stories!